Table1 Baseline characteristics of treatment-naïve patients
From: Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy
Parameters | Chronic HBV infection (Baseline) | ||||||
|---|---|---|---|---|---|---|---|
Total (n = 82) | HBeAg positive (n = 53) | HBeAg negative (n = 29) | P value | CHB (n = 62) | LC (n = 20) | P value | |
Male (n, %) | 55, 67.1% | 34, 64.2% | 21, 72.4% | 0.606 | 40, 64.5% | 15, 75.0% | 0.552 |
Median age (y,range) | 43.5(32.2–53.7) | 42.0(32.0–54.0) | 46.0(36.0–53.0) | 0.223 | 38.5(31.2–49.7) | 55.0(45.5–62.2) | < 0.05* |
Median albumin (g/L,IQR;range) | 44.4(39.9–46.5) | 43.4(38.7–45.9) | 46.2(43.3–48.7) | < 0.05* | 45.2(42.7–46.7) | 37.4(32.0–45.1) | < 0.05* |
Median bilirubin (μmol/L, IQR;range) | 16.0(12.7–24.3) | 16.4(12.9–27.2) | 15.4(11.4–18.4) | 0.322 | 16.0(12.2–21.0) | 16.1(14.3–30.2) | 0.359 |
Median ALT (U/L,IQR;range) | 66.5(34.5–121.5) | 71.0(45.0–141) | 42.0(24.0–94.0) | 0.082 | 72.0(40.5–159.8) | 66.5(34.5–121.5) | 0.024* |
Median AST(U/L, IQR;range) Detectable (n, %) HBV RNA HBV DNA | 54.5(35.2–89.5) 71(87%) 81(99%) | 63.0(43.0–92.0) 52(98%) 53(100%) | 45.0(27.0–63.0) 19(66%) 28(97%) | 0.032* | 54.0(36.0–94.3) 52(84%) 61(98%) | 60.0(35.0–70.5) 19(95%) 20(100%) | 0.574 |
Median HBV RNA (log10 copies/mL) | 4.62(3.05–5.82) | 5.57(4.07–6.43) | 2.71(0.00–4.01) | < 0.05* | 4.71(2.84–6.12) | 3.88(3.22–4.96) | 0.336 |
Median HBV DNA (log10 IU/mL) | 6.26(5.20–7.21) | 7.02(5.54–8.22) | 4.88(3.19–6.10) | < 0.05* | 6.36(5.25–7.67) | 6.03(4.95–7.03) | 0.489 |
Median qHBsAg (log10 mIU/mL) | 3,62(3.35–4.03) | 3.84(3.40–4.22) | 3.48(3.08–3.67) | < 0.05* | 3.67(3.36–4.18) | 3.53(3.34–3.72) | 0.063 |
Median LSM (kPa) | 11.80(6.85–17.88) | 11.90(8.00–21.30) | 10.20(6.70–14.50) | 0.182 | 10.00(6.38–13.85) | 21.90(14.45–36.03) | < 0.05* |